Results: 99

For: antipsychotics

The more psychotic you are, the more benefit there is in taking antipsychotics

shutterstock_122223547

John Baker reviews a recent participant-level meta-analysis of six placebo-controlled studies, which looks at the initial severity of schizophrenia and the efficacy of antipsychotics including Olanzapine, Risperidone and Amisulpride.

[read the full story...]

Medication versus placebo for anorexia nervosa: antidepressants, antipsychotics and hormonal therapy

shutterstock_47425495

In her debut blog, Nicola Coop summarises a recent meta-analysis looking at the use of antidepressants, antipsychotics and hormonal therapy for people with anorexia nervosa.

[read the full story...]

Prescribing antipsychotics in primary care: new study highlights frequent off-label use

shutterstock_146973512

Josephine Neale reports on a recent cohort study that finds less than half of UK prescriptions for antipsychotics are issued for main licensed conditions (e.g. psychosis or bipolar disorder). The research provides a reminder about the dangers of prescribing antipsychotics to people with dementia.

[read the full story...]

Childhood adversity linked to psychotropic drug use in later life

shutterstock_121428757

Andrew Jones summarises a large Finnish population-based cohort study, which finds that childhood adversities strongly predict the use of psychotropic drugs (such as antidepressants and antipsychotics) in adulthood.

[read the full story...]

Medication for the maintenance treatment of bipolar disorder

shutterstock_162124046

Elena Marcus summarises a recent network meta-analysis published in The Lancet of the comparative efficacy and tolerability of medication for the maintenance treatment of bipolar disorder.

[read the full story...]

Understanding Psychosis and Schizophrenia: a critique by Laws, Langford and Huda

Screen Shot 2014-11-25 at 17.36.49

Keith Laws, Alex Langford and Samei Huda provide a critique of the British Psychological Society Division of Clinical Psychology report published today.

[read the full story...]

Efficacy of high vs. low-potency first-generation antipsychotics for schizophrenia

Screen Shot 2014-10-03 at 13.24.52

Laurence Palfreyman summarises 3 recent Cochrane reviews, which investigate high-potency versus low-potency first-generation antipsychotic drugs for schizophrenia. The reviews find little difference in efficacy between the high-potency antipsychotics Trifluoperazine, Haloperidol, Fluphenazine, and low-potency typical antipsychotics.

[read the full story...]

Second National Audit of Schizophrenia highlights lack of progress for service users and carers

shutterstock_164147468

André Tomlin summarises the second National Audit of Schizophrenia, which highlights that many people with schizophrenia are still not getting the high quality psychological and medical treatment they deserve.

[read the full story...]